FOLH1 and Familial prostate cancer: To further examine the function of ERK5 and GPR54 in cancer immunotherapy, we generated GPR54 or ERK5 knockout PSMA‐CAR‐T cells (target of prostate cancer) using the CRISPR/Cas9 system.